ITGA2B
ENSG00000005961
Target class
Membrane receptor
Chromosome
17
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- ITGA2B
- Gene name
- Integrin subunit alpha 2b
- Gene symbol
- ITGA2B
- Previous gene symbols
- GP2B
- Protein name
- Integrin alpha-IIb (GPalpha IIb) (GPIIb) (Platelet membrane glycoprotein IIb) (CD antigen CD41) [Cleaved into: Integrin alpha-IIb heavy chain; Integrin alpha-IIb light chain, form 1; Integrin alpha-IIb light chain, form 2]
- CD41B
- CD41
- PPP1R93
- GPIIb
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Protein phosphatase 1 regulatory subunits|Integrin alpha subunits|Human platelet antigens
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 28
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 32.7
- Tissue specificity (Gini)
- 0.654
- Tissue specificity (tau)
- 0.926
- KEGG gene identifiers
- hsa:3674
- Protein interaction confidence
- 0.821271
- Protein interaction partners
- 96
- R-HSA-114608
- R-HSA-216083
- R-HSA-3000178
- R-HSA-354192
- R-HSA-354194
- R-HSA-372708
- R-HSA-445144
- R-HSA-5674135
- R-HSA-6802946
- R-HSA-6802948
- R-HSA-6802952
- R-HSA-6802955
- R-HSA-8936459
- R-HSA-9649948
- R-HSA-9656223
- R-HSA-9769733
- End position
- 44389649
- Start position
- 44372177
- Chromosome
- 17
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein .
- Plasma membrane
Publication evidence
- PubMed 20020534
- Tissue specificity (tau)
- 0.925844
- Expression inequality (Gini)
- 0.654358
Expression in transcripts per million
- Whole Blood
- 32.7
- Spleen
- 16.56
- Testis
- 10.47
- Thyroid
- 9.56
- Brain - Cerebellum
- 8.95
Expression in transcripts per million
- Whole Blood32.7
- Spleen16.56
- Testis10.47
- Thyroid9.56
- Brain - Cerebellum8.95
- Lung8.11
- Brain - Cerebellar Hemisphere7.45
- Cervix - Endocervix5.98
- Pituitary5.29
- Fallopian Tube4.78
- Cervix - Ectocervix4.48
- Ovary4.34
- Uterus3.69
- Brain - Cortex3.37
- Brain - Frontal Cortex (BA9)2.34
- Nerve - Tibial2.17
- Adipose - Visceral (Omentum)1.95
- Vagina1.91
- Brain - Hypothalamus1.75
- Prostate1.73
- Heart - Atrial Appendage1.68
- Kidney - Medulla1.57
- Esophagus - Gastroesophageal Junction1.25
- Brain - Anterior cingulate cortex (BA24)1.23
- Breast - Mammary Tissue1.19
And 29 more, listed on the interactive page.
- GO:0007229
- GO:0033631
- GO:0034113
- GO:0005886
- GO:0009986
- GO:0031092
- GO:0070062
- GO:0070442
- GO:0072562
- GO:0004895
- GO:0005515
- GO:0042802
- GO:0060090
Related records
Trials (130)
- A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
- A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
- A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
- A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI
- A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function
- A Safety Study of Eptifibatide in Patients With Sickle Cell Disease
- A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks
- A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
- A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty
- A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
- A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
- A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
- A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)
- Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
- Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis
- Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI
- Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction
- Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock
Drugs (7)
- Abciximab Integrin alpha-IIb/beta-3 inhibitor
- Eptifibatide Integrin alpha-IIb/beta-3 inhibitor
- Tadocizumab Integrin alpha-IIb/beta-3 antagonist
- Tirofiban Integrin alpha-IIb/beta-3 inhibitor
- Tirofiban hydrochloride Integrin alpha-IIb/beta-3 inhibitor
- Zalunfiban Integrin alpha-IIb/beta-3 inhibitor
- Zalunfiban acetate Integrin alpha-IIb/beta-3 inhibitor